The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Lilly; Merck; Merck Serono; Michael J. Hennessy Associates; Paradigm; Pfizer; Rgenix; Seagen; Zymeworks
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; LG Chem; MSD Oncology
Speakers' Bureau - Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Keun Wook Lee
Honoraria - Boryung; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Neeltje Steeghs
Consulting or Advisory Role - AIMM Therapeutics (Inst); Boehringer Ingelheim (Inst); Ellipses Pharma (Inst)
Research Funding - AB Science (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Cytovation (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yee Chao
No Relationships to Disclose
 
Maria Di Bartolomeo
Honoraria - Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Marc Díez Garcia
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Lilly
 
Nadia Haj Mohammad
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD (Inst)
 
Alexander Stein
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Roche; SERVIER
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
William McAdoo
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Megan Winter
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Liz Croydon
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jeeyun Lee
Consulting or Advisory Role - Mirati Therapeutics; Oncologie
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme